Education
About Us
Working with TipRanks
Follow Us
Ikena Oncology, Inc. (IKNA)
:IKNA
IKNA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.64 - $23.28
Previous CloseN/A
Volume99.58K
Average Volume (3M)25.75K
Market Cap
$69.01M
Enterprise Value-$45.67M
Total Cash (Recent Filing)$95.64M
Total Debt (Recent Filing)$5.68M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Aug 07, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding4,021,509
10 Day Avg. Volume62,162
30 Day Avg. Volume25,754
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda1.10
Forecast
1Y Price Target
$4.00Price Target Upside-73.68% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentIMG-007 has shown comparable efficacy to other OX40 therapies in development in atopic dermatitis, with a more favorable safety profile due to its non–T-cell-depleting design.
Market OpportunityThere is a blockbuster opportunity for IMG-007 in atopic dermatitis and longer-term potential in additional inflammatory and immunological indications.
Mergers And AcquisitionsThe merger with Inmagene Biopharmaceuticals is expected to provide the combined company with an estimated $175 million in cash to support development of the anti-OX40 antibody, IMG-007.
Bears Say
Clinical TrialsSanofi shared preliminary Phase II results with amlitelimab, an OX40L antibody, where the primary endpoint was not met at the highest dose level.
Financial ValuationFollowing the merger, current Ikena shareholders will own approximately 34.8% of the combined company, suggesting a combined company value of less than $300 million and enterprise value of below $120 million.
Ikena Oncology News
IKNA FAQ
What was Ikena Oncology, Inc.’s price range in the past 12 months?
Ikena Oncology, Inc. lowest stock price was $11.64 and its highest was $23.28 in the past 12 months.
What is Ikena Oncology, Inc.’s market cap?
Ikena Oncology, Inc.’s market cap is $69.01M.
When is Ikena Oncology, Inc.’s upcoming earnings report date?
Ikena Oncology, Inc.’s upcoming earnings report date is Aug 07, 2025 which is 9 days ago.
How were Ikena Oncology, Inc.’s earnings last quarter?
Ikena Oncology, Inc. released its earnings results on May 08, 2025. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.164 by -$0.006.
Is Ikena Oncology, Inc. overvalued?
According to Wall Street analysts Ikena Oncology, Inc.’s price is currently Overvalued.
Does Ikena Oncology, Inc. pay dividends?
Ikena Oncology, Inc. does not currently pay dividends.
What is Ikena Oncology, Inc.’s EPS estimate?
Ikena Oncology, Inc.’s EPS estimate is -0.13.
How many shares outstanding does Ikena Oncology, Inc. have?
Ikena Oncology, Inc. has 4,021,509 shares outstanding.
What happened to Ikena Oncology, Inc.’s price movement after its last earnings report?
Ikena Oncology, Inc. reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.164. Following the earnings report the stock price went down -0.917%.
Which hedge fund is a major shareholder of Ikena Oncology, Inc.?
Currently, no hedge funds are holding shares in IKNA
Ikena Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (-73.68% Downside)
$4.00 (-73.68% Downside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.35%
12-Months-Change
Fundamentals
Return on Equity
-23.76%
Trailing 12-Months
Asset Growth
-19.89%
Trailing 12-Months
Company Description
Ikena Oncology, Inc.
Ikena Oncology (IKNA) is a biopharmaceutical company focused on developing innovative cancer therapies. Operating within the healthcare and biotechnology sectors, Ikena leverages a deep understanding of cancer biology to create targeted oncology treatments. The company's core products are centered around its proprietary platform aimed at addressing immune-mediated and genetic drivers of cancer, with a pipeline that includes both clinical and preclinical stage drug candidates designed to improve patient outcomes.
IKNA Stock 12 Month Forecast
Average Price Target
$4.00
▼(-73.68% Downside)
Technical Analysis
Beyondspring
―
Adicet Bio
―
Precision BioSciences
―
MAIA Biotechnology, Inc.
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
―
Insiders
3.88% Mutual Funds
60.48% Other Institutional Investors
32.66% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---